This study assessed whether a cycle of `` routine '' therapeutic drug monitoring ( TDM ) for imatinib dosage individualization , targeting an imatinib trough plasma concentration ( C min ) of @,@ ng/ml ( tolerance : @-@ ,@ ng/ml ) , could improve clinical outcomes in chronic myelogenous leukemia ( CML ) patients , compared with TDM use only in case of problems ( `` rescue '' TDM ) .